Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transition metals and metal-dependent microbial targets encompass a diverse group of proteins and pathways essential for the survival, replication, and virulence of pathogens. Transition metals such as iron, zinc, manganese, and copper serve as vital cofactors for microbial enzymes involved in DNA synthesis, metabolic pathways, and the neutralization of reactive oxygen species (Hood & Skaar, 2012, Nature Reviews Microbiology). Because pathogens must scavenge these metals from the host, the machinery involved in metal acquisition, such as siderophore systems, and metal-dependent enzymes, such as metallo-beta-lactamases, are high-priority therapeutic targets (Zhu et al., 2023, Journal of Biological Chemistry). Therapeutic interventions include siderophore-antibiotic conjugates like Cefiderocol, which exploit bacterial iron uptake systems to bypass resistance mechanisms. Additionally, inhibitors like Taniborbactam are designed to block metal-dependent resistance enzymes, thereby restoring the efficacy of existing antibiotics (Simner et al., 2022, Clinical Infectious Diseases). The host immune system also participates in this process through nutritional immunity, actively sequestering metals to starve invading microbes. A primary challenge in targeting these systems is ensuring selectivity to avoid inhibiting human metalloproteins, such as matrix metalloproteinases or carbonic anhydrases. Such off-target interactions could lead to significant systemic toxicity or disruption of host metal homeostasis (Cassat & Skaar, 2013, Cell Host & Microbe). Consequently, drug development in this space requires precise mapping of the structural differences between microbial and human metal-binding sites.
Drugs targeting these systems function by sequestering essential metal ions (chelation), utilizing microbial metal transporters for drug entry (siderophore-drug conjugates), or inhibiting the catalytic activity of metal-dependent enzymes (metalloenzyme inhibition) (Zhu et al., 2023, Journal of Biological Chemistry).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transition metals and metal-dependent microbial targets.